Newly diagnosed mantle cell lymphoma study with Hanlikang and BTK drugs
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies how well Hanlikang and a BTK inhibitor work for people newly diagnosed with mantle cell lymphoma. The goal is to improve lymphoma control while checking safety, since you must meet specific blood, organ, and health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–70 years old and can do daily activities fairly normally (ECOG 0 to 2)
- Your lymphoma was confirmed on pathology, and you are expected to live more than 6 months
- You have measurable tumor spots on scans (or specific sizes for lymph node or other lesions)
- Your blood counts and organ tests are high enough (like neutrophils, platelets, and hemoglobin) and liver/kidney function are acceptable
- You can safely take the study treatments: no major heart problems and no chemotherapy contraindications
- You have not taken other cancer treatments (including certain traditional anti-cancer medicines or immunotherapy) recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two targeted drugs for people with mantle cell lymphoma that has not responded to or has returned after treatment with a BTK inhibitor. The drugs aim to block cancer cell growth and survival pathways to potentially control the disease.
This study tests a combination treatment for people with mantle cell lymphoma that has come back or not responded to a BTK inhibitor. It aims to see if this new approach can help control the cancer.
This trial tests a new combination of medications for mantle cell lymphoma that has returned or not responded to other treatments. The goal is to see if this combination can shrink tumors and is safe for patients like you.
This trial is testing a combination of three drugs (polatuzumab vedotin, bendamustine, and rituximab) for people with mantle cell lymphoma that has progressed after a BTK inhibitor. The goal is to see if this combination can help control the lymphoma. You'll receive the treatment intravenously (by IV) over several cycles.
This trial tests a new combination of two targeted drugs (pacritinib plus a BTK inhibitor like ibrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. It may help if your current BTK inhibitor is no longer working well.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
Hear when a new Newly Diagnosed Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.